Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2016 (2016), Article ID 5361569, 6 pages
http://dx.doi.org/10.1155/2016/5361569
Review Article

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature

Department of Dermatology, Ministry of Health Diskapi Yildirim Beyazit Education and Research Hospital, 06110 Ankara, Turkey

Received 30 November 2015; Revised 7 February 2016; Accepted 15 February 2016

Academic Editor: Jean Kanitakis

Copyright © 2016 Bilgen Gençler and Müzeyyen Gönül. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The incidence of melanoma has recently been increasing. BRAF mutations have been found in 40–60% of melanomas. The increased activity of BRAF V600E leads to the activation of downstream signaling through the mitogen-activated protein kinase (MAPK) pathway, which plays a key role as a regulator of cell growth, differentiation, and survival. The use of BRAF inhibitors in metastatic melanoma with BRAF mutation ensures clinical improvement of the disease. Vemurafenib and dabrafenib are two selective BRAF inhibitors approved by the Food and Drug Administration (FDA). Both drugs are well tolerated and successfully used in clinical practice. However, some adverse reactions have been reported in patients in the course of treatment. Cutaneous side effects are the most common adverse events among them with a broad spectrum. Both the case reports and several original clinical trials reported cutaneous reactions during the treatment with BRAF inhibitors. In this review, the common cutaneous side effects of BRAF inhibitors in the treatment of metastatic melanoma with BRAF V600E mutation were reviewed.